Table 1

Demographic and baseline characteristics

 PlaceboPH-797804 dose group
0.5 mg3 mg6 mg10 mg
N4520477048
Age (years)64 (7.6)64 (9.5)62 (7.8)65 (7.0)65 (6.8)
Men26 (58%)12 (60%)32 (68%)55 (79%)38 (79%)
Weight (kg)72.8 (16.3)70.4 (11.3)74.5 (16.3)77.0 (13.9)77.1 (13.6)
Current smoker18 (40%)2 (10%)23 (49%)21 (30%)16 (33%)
Time since diagnosis (years)5.3 (0.8, 19.3)7.1 (0.6, 28.0)5.1 (0.9, 30.8)6.0 (0.7, 21.0)5.7 (0.6, 19.0)
Trough FEV1 at baseline (ml)1080 (370)1230 (400)1270 (500)1400 (420)1380 (540)
FEV1/FVC ratio at screening0.44 (0.11)0.46 (0.10)0.46 (0.11)0.47 (0.11)0.47 (0.10)
% Predicted FEV1 at screening47 (10.0)56 (12.0)53 (10.9)56 (12.7)56 (12.2)
  • Data are mean (SD), number (%) or mean (min–max). Data are from the safety analysis set (ie, all patients who received at least one dose of PH-797804/placebo), except for trough FEV1 at baseline, FEV1/FVC ratio and % predicted FEV1 at screening which are from the full analysis set.

  • FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity.